Showing 741 - 760 results of 230,837 for search '(( 10 ((a decrease) OR (mean decrease)) ) OR ( 5 ((a decrease) OR (mean decrease)) ))', query time: 2.09s Refine Results
  1. 741
  2. 742

    Administration of APB5, but not APA5, decreases the hyperplasia of alveolar type 2 epithelial cells induced by BLM. by Masami Kishi (6167105)

    Published 2018
    “…The administration of APB5 markedly decreased the hyperplasia of type 2 epithelial cells induced by BLM. …”
  3. 743
  4. 744
  5. 745
  6. 746
  7. 747
  8. 748
  9. 749
  10. 750
  11. 751

    Increasing TPP side chain length decreases melanoma cell viability and clonogenic survival. by Kyle C. Kloepping (9928265)

    Published 2020
    “…<p>(A) A375 and (B) MeWo melanoma cells were treated with 0.5 μM 5-, 8-, 10-, 12-,14-, or 16-TPP for 24 h, 48 h, or 72 h and analyzed for cell viability by the MTT method (* significant relative to control; p<0.05; N = 4). …”
  12. 752
  13. 753

    List of Included studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  14. 754

    The search strategy in three databases. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  15. 755

    NIH score. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  16. 756

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  17. 757
  18. 758
  19. 759
  20. 760